Moleculin Biotech, Inc. (MBRX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Moleculin Biotech, Inc. (MBRX) closed at USD 0.41 on 2026-10-14, a change of -96.6 % over the past year, with a market capitalization of USD 7.54M.

Moleculin Biotech, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Moleculin Biotech, Inc. key figures

Previous close

USD 0.41 (2026-10-14)

1-year change

-96.6 %

Market cap

USD 7.54M

Enterprise value

USD 238,578

P/E ratio (trailing)

0.05

P/E ratio (forward)

-0.00

EPS (trailing)

7.73

EPS (forward)

-110.50

PEG ratio

n/a

Price to book

0.23

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.17

Employees

17

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Moleculin Biotech, Inc. and compare it with other stocks.